On July 29, 2026, the European Commission granted marketing authorization for the Pfizer-BioNTech 2026-2027 COVID-19 vaccine formula targeting the XFG variant of the JN.1 lineage. The approval covers individuals aged 6 months and older across all 27 EU Member States, Iceland, Liechtenstein, and Norway. This follows a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use on July 23, 2026. BioNTech has initiated manufacturing of the monovalent vaccine to ensure supply readiness for the upcoming respiratory disease season. BioNTech SE is a global biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases.

BioNTech SE has announced an update regarding its share repurchase program, which allows the Company to purchase American Depositary Shares (ADSs) for an aggregate amount of up ability to $1.0 billion. The buyback period commences on June 8, 2026, and is scheduled to authorization to conduct the ability to conduct the buyback program through May authorization to conduct the ability to conduct the buyback program through May 6, 2027.